Skip to content

Study · Randomized controlled trial · n = 124 · 2022

7 results

Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.

Maselli D, Atieh J, Clark MM, Eckert D, Taylor A, Carlson P, Burton DD, Busciglio I, Harmsen WS, Vella A, Acosta A, Camilleri M

Obesity (Silver Spring, Md.)1 Aug 2022Cited by 111 (Europe PMC)

PMID35894080 (opens in a new tab)PMCIDPMC9335902 (opens in a new tab)DOI10.1002/oby.23481 (opens in a new tab)PepBankPUB-35894080
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide increased weight loss compared with placebo at 5 and 16 weeks.

    In plain wordsIn adults with obesity, liraglutide led to more weight loss than placebo at 5 and 16 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseWeight loss at 5 and 16 weeks
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    escalated to 3 mg daily · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Relative to placebo, liraglutide increased weight loss at 5 and 16 weeks (both p < 0.05)
    1 context sentence
    Summary · context
    The study conducted a randomized, parallel-group, placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg subcutaneously daily in 136 otherwise healthy adults with obesity.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide slowed the gastric emptying half-time of solids compared with placebo at 5 and 16 weeks.

    In plain wordsIn adults with obesity, liraglutide slowed how fast the stomach emptied solid food compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastric emptying half-time of solids (T1/2) at 5 and 16 weeks
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    escalated to 3 mg daily · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    slowed time to half GES (T1/2 ) at 5 and 16 weeks (both p < 0.001)
    1 context sentence
    Summary · context
    The study conducted a randomized, parallel-group, placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg subcutaneously daily in 136 otherwise healthy adults with obesity.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide increased fasting gastric volume compared with placebo at 16 weeks.

    In plain wordsIn adults with obesity, liraglutide increased the stomach volume when fasting compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseFasting gastric volume at 16 weeks
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    escalated to 3 mg daily · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    increased fasting gastric volume (p = 0.01)
    1 context sentence
    Summary · context
    The study conducted a randomized, parallel-group, placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg subcutaneously daily in 136 otherwise healthy adults with obesity.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide increased satiation compared with placebo at 16 weeks.

    In plain wordsIn adults with obesity, liraglutide increased the feeling of fullness compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseSatiation at 16 weeks
    Study

    n = 124

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    escalated to 3 mg daily · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    satiation (p < 0.01) at 16 weeks.
    1 context sentence
    Summary · context
    The study conducted a randomized, parallel-group, placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg subcutaneously daily in 136 otherwise healthy adults with obesity.
  5. 05HumanRandomized controlled trialMechanism

    In adults with obesity on liraglutide, slower gastric emptying half-time of solids was positively correlated with weight loss.

    In plain wordsIn adults with obesity on liraglutide, slower stomach emptying was linked to more weight loss.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of gastric emptying half-time with weight loss
    Study

    n = 59

    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    escalated to 3 mg daily · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    GES T1/2 was positively correlated with weight loss on liraglutide (both p < 0.001).
    1 context sentence
    Summary · context
    The study conducted a randomized, parallel-group, placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg subcutaneously daily in 136 otherwise healthy adults with obesity.
  6. 06HumanRandomized controlled trialOther

    In adults with obesity on liraglutide for 16 weeks, GLP1R rs6923761 AG/AA carriers had lower percent body fat than GG carriers, but the difference did not reach statistical significance (p = 0.062).

    In plain wordsIn adults with obesity on liraglutide, a GLP1R gene variant was linked to a lower body fat percentage, but not at a statistically significant level.

    Peptide
    Liraglutide
    Outcome
    No significant changeGLP1R rs6923761 genotype and percent body fat
    Study

    n: not reported in source

    Comparator
    GG genotype
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    escalated to 3 mg daily · subcutaneous · 16 weeksAs given in this study (human).

    Measurements

    p value
    0.062
    AG/AA vs GG, percent body fat

    Source sentences

    Summary
    After 16 weeks of liraglutide, GLP1R rs6923761 (AG/AA vs. GG) was associated with reduced percent body fat (p = 0.062)
    1 context sentence
    Summary · context
    The study conducted a randomized, parallel-group, placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg subcutaneously daily in 136 otherwise healthy adults with obesity.
  7. 07HumanRandomized controlled trialOther

    In adults with obesity on liraglutide for 16 weeks, TCF7L2 rs7903146 CC carriers had lower body weight than CT/TT carriers (p = 0.015).

    In plain wordsIn adults with obesity on liraglutide, a TCF7L2 gene variant was linked to lower body weight.

    Peptide
    Liraglutide
    Outcome
    DecreaseTCF7L2 rs7903146 genotype and body weight
    Study

    n: not reported in source

    Comparator
    CT/TT genotype
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    escalated to 3 mg daily · subcutaneous · 16 weeksAs given in this study (human).

    Measurements

    p value
    0.015
    CC vs CT/TT, body weight

    Source sentences

    Summary
    TCF7L2 rs7903146 (CC vs. CT/TT) was associated with lower body weight (p = 0.015).
    1 context sentence
    Summary · context
    The study conducted a randomized, parallel-group, placebo-controlled, 16-week trial of liraglutide, escalated to 3 mg subcutaneously daily in 136 otherwise healthy adults with obesity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02647944

Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

Mayo Clinicn = 4018 Dec 2015 to 30 Dec 2016

Obesity

Trial pageClinicalTrials.govUpdated 27 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.